Akamis Bio
Industry
- Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
- Transgenics
- Pharmaceuticals
Other Names/Subsidiaries
- Hybrid Biosystems
- Myotec Therapeutics
- PsiOxus Therapeutics
Latest on Akamis Bio
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Kaken Obtains Aadi’s Fyarro, Comm
Venture capital mega-rounds of $100m or more have surged in 2024 and the trend has continued in December, with announcements on 19 December that Ottimo Pharma’s series A round brought in more than $14
Coya Therapeutics, Inc. launched the final biopharmaceutical initial public offering in the US in 2022 on 29 December, raising $15.25m from the sale of 3.05 million shares at $5 each, which brought t
Cancer vaccines have gained in prominence over the last couple of decades, as the emergence of immuno-oncology has validated the immune system’s essential role in maintaining healthy cell division. Th